The FDA gave HeartSine’s Samaritan defibrillator recall Class I status over concerns that battery issues could lead to patient injury or death.
The Samaritan 300/300P public access defibrillators, which were found to intermittently turn off and on, may be unable to deliver therapy during a cardiac event due to the battery defects.
The affected products include those with the following serial numbers, which were manufactured and distributed from 08/01/2004 to 01/31/2011:
0400000501 to 0700032917
08A00035000 to 10A0070753
10C00200000 to 10C00210106
U.K. medical device maker HeartSine Technologies earlier this month launched a global correction of its Samaritan defibrillators after finding that the devices failed to provide therapy due to a pair of battery defects.
There were no deaths or injuries reported within this issue. HeartSine has not yet conclusively determined whether 5 reported deaths were related to the battery issues, according to the FDA comments.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.